SLC9A2 loss enhances colorectal cancer metastasis and immunotherapy resistance by inhibiting STAT3 signaling and angiogenesis, establishing it as a key tumor suppressor and biomarker for colorectal cancer. Here, STAT3 is linked to neoplasm.